EUCTR2004-001178-13-LT进行中（未招募）不适用
An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADE(TM) (EAP)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The patient was previously diagnosed with multiple myeloma based on standard criteria.
- •The patient has received at least 2 previous lines of therapy for multiple myeloma and, in the investigators opinion, is refractory to or has relapsed after the last therapy.
- •The patient is of a legally consenting age, as defined by local regulations, and is >18 years of age.
- •The patient is, in the investigators opinion, willing and able to comply with the protocol requirements.
- •The patient has given voluntary written informed consent before performance of any studyrelated procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to his or her future medical care.
- •If female, the patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) from Screening through the Final Visit.
- •If male, the patient agrees to use an acceptable barrier method for contraception from Screening through the Final Visit.
- •The patient has a Karnofsky performance status >60 (see Attachment 1).
- •The patient meets the following pretreatment laboratory criteria at and within 21 days before baseline (Day 1 of Cycle 1, before study drug administration):
- •Platelet count >30x 109/L, with or without transfusion support.
- •Hemoglobin >7.0 g/dL, with or without transfusion support
- •Absolute neutrophil count (ANC) >0.5 x 109/L.
- •Serum calcium <3.5 mmol/L (14 mg/dL).
- •Aspartate transaminase (AST): <2.5 x the upper limit of normal (ULN).
- •Alanine transaminase (ALT): <2.5 x the ULN.
- •Total bilirubin: <1.5 x the ULN.
- •Calculated (see Attachment 2) or measured creatinine clearance:
- •>30 mL/minute.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •If the patient received VELCADE in a previous clinical trial, the patients best response to VELCADE was progressive disease.
- •If the patient received VELCADE in a previous trial, the patient experienced one or more serious adverse events.
- •Patient received nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment.
- •Patient received corticosteroids (>10 mg/day of prednisone or equivalent) within 3 weeks before enrollment.
- •Patient received immunotherapy or antibody therapy within 4 weeks before enrollment.
- •Patient has received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment.
- •Patient had major surgery within 4 weeks before enrollment. (Kyphoplasty is not considered major surgery.)
- •Patient has a history of allergic reaction attributable to compounds containing boron or mannitol.
- •Patient has peripheral neuropathy of Grade 2 or greater intensity, as defined by the NCI Common Toxicity Criteria (NCI CTC), as follows: Grade 2: Objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with activities of daily living (ADLs); Grade 3: Sensory loss or paresthesia interfering with ADLs; Grade 4:Permanent sensory loss that interferes with function.
- •Patient had a myocardial infarction within 6 months of enrollment or has New NYHA Class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- •Patient has cardiac amyloidosis.
- •Patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
- •Patient known to be HIV-positive.
- •Patient is known to be hepatitis B surface antigen-positive or has known active hepatitis C infection.
- •Patient has an active systemic infection requiring treatment.
- •If female, the patient is pregnant or breast-feeding. Confirmation that the patient is not pregnant must be established by a negative serum -hCG pregnancy test during Screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
研究者
相似试验
进行中（未招募）
不适用
An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADEPatients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory to or have relapsed after their last therapy for multiple myelomaClassification code 10028228EUCTR2004-001178-13-LVJanssen Cilag International NV750
进行中（未招募）
1 期
An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADE(TM) (EAP)EUCTR2004-001178-13-CZJanssen-Cilag, div.Johnson and Johnson s.r.o.
尚未招募
Unknown
Establishment of an international method of Association Therapy for prevention of frailty in the older people at home and varification of its effectiveness.oneJPRN-UMIN000051596Tohoku Bunka Gakuen University140
尚未招募
不适用
A study following people with haemophilia A and B, with or without inhibitors, when on usual treatment (explorerââ??¢6)CTRI/2019/03/018292ovo Nordisk India Private Ltd
招募中
3 期
INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR CHILDREN AND ADOLESCENTS WITH LANGERHANS CELL HISTIOCYTOSISLangerhans cell histiocytosisNL-OMON50201Stichting Kinderoncologie Nederland85